Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CRHBP | P24387 | 2/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.51 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL67237 | 0.98 | LMNA (0.59) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL65737 | 0.98 | LMNA (0.59) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL20769804 | 0.98 | LMNA (0.59) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL29757088 | 0.98 | LMNA (0.59) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL1715 | 0.98 | LMNA (0.59) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL9171150 | 0.96 | LMNA (0.58) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL16820451 | 0.96 | LMNA (0.58) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL2008283 | 0.96 | LMNA (0.58) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| Methane SCHEMBL7338694 | 0.96 | LMNA (0.58) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL29272545 | 0.96 | LMNA (0.58) | LMNAHSD17B10CYP2C19ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1847274-A1 | Association of phenylbutyrate, ATRA and cytidine and its use in anti-tumour therapy | CIPROSA LLC - Corporate Creations Network, Inc. (US) | 2007-10-24 | — | — | EP | claimed |
| US-20250377351-A1 | METHOD FOR IDENTIFYING EFFECTIVE TREATMENTS AGAINST NEURODEGENERATIVE DISORDERS | AcuraStem Incorporated (US) | 2025-12-11 | — | — | US | disclosed |
| US-20240041807-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2024-02-08 | — | — | US | disclosed |
| US-11819483-B2 | Combination therapy to treat urea cycle disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230181504-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2023-06-15 | — | — | US | disclosed |
| CN-115645536-A | Mouse myopia induction model and endoplasmic reticulum stress inhibitor for myopia prevention/inhibition | 坪田实验室股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115645535-A | Mouse myopia induction model and endoplasmic reticulum stress inhibitor for myopia prevention/inhibition | 坪田实验室股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11517547-B2 | Combination therapy to treat urea cycle disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2022-12-06 | — | — | US | disclosed |
| CN-110392579-B | Mouse myopia induction model and endoplasmic reticulum stress inhibitor for myopia prevention/inhibition | 坪田实验室股份有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-114306306-A | Application of 2-bromopalmitic acid in preparation of medicine for treating spermatogenic dysfunction related diseases | 中国人民解放军东部战区总医院 | 2022-04-12 | — | — | CN | disclosed |
| US-9296716-B2 | Androgen receptor ligands | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIV. TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2016-03-29 | — | — | US | disclosed |
| CN-105176930-A | Reprogramming cells | SCRIPPS RESEARCH INST | 2015-12-23 | — | — | CN | disclosed |
| CN-104981458-A | Inhibitors of histone demethylases | EPITHERAPEUTICS APS | 2015-10-14 | — | — | CN | disclosed |
| CN-102959076-B | Reprogramming cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-09-16 | — | — | CN | disclosed |
| US-20140357682-A1 | ANDROGEN RECEPTOR LIGANDS | The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy (IE) | 2014-12-04 | — | — | US | disclosed |
| EP-2782643-A1 | ANDROGEN RECEPTOR LIGANDS | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin (IE) | 2014-10-01 | — | — | EP | disclosed |
| EP-2698155-A1 | Pharmaceutical unit dosage form comprising 4-phenylbutyric acid | Lunamed AG (CH) | 2014-02-19 | — | — | EP | disclosed |
| WO-2013076275-A1 | ANDROGEN RECEPTOR LIGANDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIV.TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2013-05-30 | — | — | WO | disclosed |
| CN-102959076-A | Reprogramming cells | SCRIPPS RESEARCH INST | 2013-03-06 | — | — | CN | disclosed |
| EP-1847274-A1 | Association of phenylbutyrate, ATRA and cytidine and its use in anti-tumour therapy | CIPROSA LLC - Corporate Creations Network, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357682-A1 | ANDROGEN RECEPTOR LIGANDS | AR, NR5A1, SHBG | LMNA 1344/4885HSD17B10 333/4885CYP2C19 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.